McLean Fiona
Department of Rheumatology, Charing Cross Hospital, Fulham Palace Road, London W6 8RE.
Br J Biomed Sci. 2013;70(1):10-4. doi: 10.1080/09674845.2013.11669923.
Previous research carried out in the area of autoimmune liver disease and autoantibody specificity has not been conclusive, and correlation between the two in most situations remains unclear. This study aims to facilitate a consensus on these autoantibodies in an unselected patient population and their relationship to autoimmune liver disease (AILD). The study detected two autoantibodies that show reasonable specificity for primary biliary cirrhosis (PBC), anti-sp100 and anti-gp210, and it may be clinically useful to report any antimitochondrial antibody (AMA) detected, as this may be a sign of very early PBC. The inter-methodological differences in assays available for detection of the autoantibodies were also noted. Care must be taken when selecting methods to detect these autoantibodies.
先前在自身免疫性肝病和自身抗体特异性领域开展的研究尚无定论，在大多数情况下，两者之间的相关性仍不明确。本研究旨在就未经过筛选的患者群体中的这些自身抗体及其与自身免疫性肝病（AILD）的关系达成共识。该研究检测到两种对原发性胆汁性肝硬化（PBC）具有合理特异性的自身抗体，即抗sp100和抗gp210，报告检测到的任何抗线粒体抗体（AMA）可能具有临床意义，因为这可能是早期PBC的迹象。还注意到可用于检测自身抗体的检测方法之间的方法学差异。在选择检测这些自身抗体的方法时必须谨慎。
